

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196
Inventors: Salceda et al.
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating Prostate
Cancer

"Express Mail" Label No: EL718096860US
Date of Deposit: April 10, 2001

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Assistant Commissioner for Patents, Box PCT,
Washington, D.C. 20231.

By

Deborah E. Ehret

Typed Name: Deborah Ehret

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.
§§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below; or
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

- (XX) All listed references are in the English language.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: April 10, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Sheet 01 of 01


Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DEX-0196	Serial No. Not Yet Assigned
		Applicant Salceda et al.	
		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Bussemakers et al., "DD3:A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer ¹ ", <i>Cancer Research</i> 1999 59(23):5975-5979	
	AB	Cho-Chung Y.S., "Antisense oligonucleotides for the treatment of cancer", <i>Curr. Opin. Thera. Patents</i> 1993 3(12):1737-1750	
	AC	Olsson et al., "Reverse Transcriptase-Polymerase Chain Reaction Assays for Prostate Cancer", <i>Urologic Clinics of North America</i> 1997 24(2):367-378	
EXAMINER		DATE CONSIDERED	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196
Inventors: Salceda et al.
Serial No.: 09/807,201
Filing Date: April 25, 2001
Examiner: Unknown
Group Art Unit: 1642
Title: Method of Daignosing, Monitoring,
Staging, Imaging and Treating
Prostate Cancer

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date:


Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above

identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() A copy of the of the PCT Search Report for @@ which corresponds to the subject US application @@ is included.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were

previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

- () Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: @@ (@@). Full text of abbreviated reference is available if requested.
- () Reference @@ is in a foreign language therefore a Geneseq Patent search report is attached to demonstrate relevance.
- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- () All listed references are in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,


Nathan P. Letts
Registration No. 36,581

Date: 12/17/2001

DiaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 246-6400

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Serial Number 09/807,201

Filing Date April 25, 2001

Applicant Salceda et al.

Group Art Unit 1842

Examiner Name Unknown

Attorney Docket Number DEX-0196

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass
	AA	US5514579	05/07/1996	O'Hara et al.		
	AB	US5952011	09/14/1999	O'Hara et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation/ Comments
	AC	EP 1033401 A2	09/06/2000	Dumas Milne Edwards et al.			
	AD	WO 93/13207 A2	07/05/1993	O'HARA et al.			
	AE	WO 98/20165 A2	05/14/1998	LANDER et al.			
	AF	WO 99/37811 A1	07/29/1999	AN et al.			
	AG	WO 00/04148 A2	01/27/2000	DILLON et al.			
	AH	WO 00/14234 A1	03/18/2000	AN et al.			
	AI	WO 00/23111 A1	04/27/2000	SALCEDA et al.			
	AJ	WO 01/25272 A2	04/12/2001	XU et al.			
	AK	WO 01/34802 A2	05/17/2001	XU et al.			
	AL	WO 01/51633 A2	07/19/2001	XU et al.			

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Serial Number	09/807,201
Filing Date	April 25, 2001
Applicant	Salceda et al.
Group Art Unit	1842
Examiner Name	Unknown
Attorney Docket Number	DEX-0196

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Author, title of the article, title of the item, date, volume-issue number, page(s).	Translation/Comments
	AM	An G, Meka CS, Bright SP, Veltri RW. Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. <i>Urology</i> . 1999 Dec;54(6):1105-11.	
	AN	Dubbink HJ, Cleutjens KB, van der Korput HA, Trapman J, Romijn JC. An Sp1 binding site is essential for basal activity of the human prostate-specific transglutaminase gene (TGM4) promoter. <i>Gene</i> . 1999 Nov 29, Vol.240(2), pages 261-7.	
	AO	Dubbink HJ, Hoedemaeker RF, van der Kwast TH, Schroder FH, Romijn JC. Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern. <i>Lab Invest</i> . 1999 Feb, Vol. 79(2), pages 141-50.	
	AP	Dubbink, H.J., de Waal, L., van Haperen, R., Verkalk, N.S., Trapman, J. and Romijn, J.C. The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterization. <i>Genomics</i> , Vol. 51(3), 1998, pages 434-444.	
	AQ	Dubbink, H.J., Verkalk, N.S., Faber, P.W., Trapman, J., Schroder, F.H. and Romijn, J.C. Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. <i>Biochem. J.</i> Vol. 315(Pt 3), 1996, pages 901-908.	
	AR	Gentile V, Grant FJ, Porta R and Baldini A. Localization of the human prostate transglutaminase (type IV) gene. (TGM4) to chromosome 3p21.33-p22 by fluorescence in situ hybridization. <i>Genomics</i> , Vol.27(1), 1995, pages 219-220.	
	AS	Goebel HW, Rausch U, Steinhoff M, Seitz J, Bacher M, Papotti M, Bussolati G, Tuohimaa P, Aumuller G. Arguments against the prostatic origin of the R-3327 Dunning H tumor. <i>Virchows Arch B Cell Pathol Incl Mol Pathol</i> . 1992, Vol.62(1), pages 9-18.	
	AT	Grant FJ, Taylor DA, Sheppard PO, Mathewes SL, Lint W, Vanaja E, Bishop PD and O'Hara PJ. Molecular cloning and characterization of a novel transglutaminase cDNA from a human prostate cDNA library. <i>Biochem. Biophys. Res. Commun.</i> Vol.203(2), 1994, pages 1117-1123.	

Examiner
SignatureDate
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196
Inventors: Salceda et al.
Serial No.: 09/807,201
Filing Date: 25 April 2001
Examiner: Unknown
Group Art Unit: 1642
Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating
Prostate Cancer

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: June 13, 2002



Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- () A copy of the of the PCT Search Report for PCT Application @@ which corresponds to the subject US application @@ is included.
- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were


previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

(XX) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: WO WO 98/45435 A2 (Pages 1-44, 53, 56-92, 505-506, 590-631); WO 99/06548 A2 (Pages 1-148, Figs 1-4, Sequence Listing 1, SL 343-346). Full text of abbreviated reference is available if requested.

() Reference @@ is in a foreign language. Therefore, a Geneseq Search report is attached to demonstrate relevance.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,



Nathan P. Letts
Registration No. 36,581

Date: June 13, 2002

DiaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 246-6400

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Serial Number 09/807,201

Filing Date 25 April 2001

Applicant Salceda et al

Group Art Unit 1642

Examiner Name Unknown

Attorney Docket Number DEX-0196

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation/ Comments
	AA	WO 98/45435 A2	10/15/1998	Jacobs et al.			Abbreviated
	AB	WO 99/06548 A2	2/11/1999	Dumas Milne Edwards et al.			Abbreviated
	AC	WO 99/57132 A1	11/11/1999	Jacobs et al.			
	AD	WO 00/12706 A1	03/09/2000	Pastan et al.			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Author, title of the article, title of the item, date, volume-issue number, page(s).	Translation/ Comments
	AE	Brinkmann et al. <i>PAGE-1</i> , an X chromosome-linked <i>GAGE</i> -like gene that is expressed in normal and neoplastic prostate, testis, and uterus. PNAS. Sept 1998;95:10757-10762.	
	AF	Chen et al. Isolation and characterization of <i>PAGE-1</i> and <i>GAGE-7</i> . JBC. 10 July 1998;273(28):17618-17625.	
	AG	Dannull et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Can. Res. 1 Oct 2000;60(19):5323-5598.	

Examiner
SignatureDate
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196
Inventors: Salceda et al.
Serial No.: 09/807,201
Filing Date: 25 April 2001
Examiner: Davis, M T
Group Art Unit: 1642
Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating
Prostate Cancer

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: 31 July 2002


Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

- (xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

- () A copy of the of the PCT Search Report for PCT Application @@ which corresponds to the subject US application @@ is included.

- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were


previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

(xx) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: WO 00/55351 A1 (Pages 1-13, 73, 89-95, 134-150, 168-401, 465-469, Sequence Listing 1, SL 484-486, International Search Report); WO 00/735454 A1 (pages 1-591, figures 207-208, ISR). Full text of abbreviated reference is available if requested.

() Reference @@ is in a foreign language. Therefore, a Geneseq Search report is attached to demonstrate relevance.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,



Nathan P. Letts
Registration No. 36,581

Date: 31 July 2002

DiaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 246-6400

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Serial Number

06/07/201

Filing Date

25 April 2001

Applicant

Salceda et al

Group Art Unit

1642

Examiner Name

Davis, M T

Attorney Docket Number

DEX-0196

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date MM-DD-YYYY
	AA	6,043,033	03/28/2000	Bandman et al.			02/27/1997
	AB	6,203,979	03/20/2001	Bandman et al.			01/16/1998
	AC	6,262,245	07/17/2001	Xu et al.			02/25/1998
	AD	6,294,663	09/25/2001	O'Brien et al.			03/02/2000
	AE	6,350,448	02/26/2002	Bandman et al.			01/07/2000

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation/ Comments
	AF	JP 11032768 A2	02/09/1999	Hiroshi et al.			No Trans/ Front Page
	AG	WO 98/36054 A1	08/20/1998	Antalis et al.			
	AH	WO 98/37093 A2	08/27/1998	Xu et al.			
	AI	WO 98/37418 A2	08/27/1998	Xu et al.			
	AJ	WO 99/14328 A2	03/25/1999	Wood et al.			
	AK	WO 99/36550 A2	07/22/1999	Bandman et al.			
	AL	WO 99/60162 A1	11/25/1999	Ali et al.			
	AM	WO 99/62941 A2	12/09/1999	Afar et al.			
	AN	WO 99/62942 A2	12/09/1999	Afar et al.			
	AO	WO 00/00605 A1	01/06/2000	Wong et al.			
	AP	WO 00/12758 A1	03/09/2000	Salceda et al.			
	AQ	WO 00/18805 A1	03/30/2000	Ali et al.			
	AR	WO 00/18961 A2	04/06/2000	Macbeth et al.			
	AS	WO 00/29448 A2	05/25/2000	Kato et al.			
	AT	WO 00/36107 A2	06/22/2000	Mitcham et al.			
	AU	WO 00/43495 A2	07/27/2000	Rosen et al.			
	AV	WO 00/55351 A1	09/21/2000	Rosen et al.			Abbreviated
	AW	WO 00/55629 A2	09/21/2000	Mack et al.			
	AX	WO 00/73454 A1	12/07/2000	Ashkenazi et al.			Abbreviated
	AY	WO 00/76531 A1	12/21/2000	Rosen et al.			
	AZ	WO 00/78960 A2	12/28/2000	Yuqiu et al.			
	BA	WO 01/04311 A1	01/18/2001	Ashkenazi et al.			
	BB	WO 01/16289 A2	03/08/2001	Darrow et al.			
	BC	WO 01/23547 A1	04/05/2001	Komatsoullis et al.			
	BD	WO 01/27257 A1	04/19/2001	O'Brien et al.			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Author, title of the article, title of the item, date, volume-issue number, page(s).	Translation/ Comments
	BE	Paoloni-Giacobino et al. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3, Genomics, 1997; 44:309-320.	
	BF	Pasquall et al. Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. J Clin Endocrin & Metab. 1999;84(4):1463-1469.	

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196
Inventors: Salceda et al.
Serial No.: 09/807,201
Filing Date: April 25, 2001
Examiner: Minh Tam B Davis
Group Art Unit: 1642
Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating Prostate
Cancer

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202

On this date: January 23, 2003

Kathleen A. Tyrrell, Registration No. 38,350

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: January 23, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Sheet 01 of 01

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DEX-0196	Serial No. 09/807,201
		Applicant Salceda et al.	
		Filing Date April 25, 2001	Group 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	Blok et al., "Isolation of cDNAs That Are Differentially Expressed Between Androgen-Dependent and Androgen-Independent Prostate Carcinoma Cells Using Differentially Display PCR", The Prostate 1995 26:213-224		
CB	Chang et al., "Differentially Expressed Genes in Androgen-dependent and -independent Prostate Carcinomas", Cancer Research 1997 57:4075-4081		
CC	Friedrich et al., "Differentiation-Stage Specific Expression of Oncoprotein 18 in Human and Rat Prostatic Adenocarcinoma", The Prostate 1995 27:102-109		
CD	Gagnon et al., "Expression of Zn-Alpha ² -Glycoprotein and PSP-94 in Prostatic Adenocarcinoma", American Journal of Pathology 1990 136(5):1147-1152		
CE	Hale et al., "Zinc α -2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer", Clinical Cancer Research 2001 7(7):846-853		
CF	López-Otín et al., "Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic and Biochemical Features", Endocrine Reviews 1998 19(4):365-396		
CG	Olsson et al., "Reverse Transcriptase-Polymerase Chain Reaction Assays for Prostate Cancer", Urologic Clinics of North America 1997 24(2):367-378		
CH	Ueyama et al., "Molecular Cloning and Chromosomal Assignment of the Gene for Human Zn- α_2 -glycoprotein", Biochemistry 1993 32:12968-12976		
CI	EMBL/GenBank/DBJ X0-002220465 -Ueyama et al., "Molecular Cloning and Chromosomal Assignment of the Gene for Human Zn- α_2 -glycoprotein", Biochemistry 1993 32:12968-12976		
EXAMINER		DATE CONSIDERED	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0196
Inventors: Salceda et al.
Serial No.: 09/807,201
Filing Date: April 25, 2001
Examiner: Minh Tam B Davis
Group Art Unit: 1642
Title: Method of Diagnosing, Monitoring,
Staging, Imaging and Treating Prostate
Cancer

I, Kathleen A. Tyrrell, Registration No. 38,350,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: May 12, 2003


Kathleen A. Tyrrell, Registration No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.
§§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

() In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

(XX) The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: May 19, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Sheet 01 of 02

Form PTO-1449 Modified		Docket No. DEX-0196	Serial No. 09/807,201
List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Applicant Salceda et al.	
		Filing Date April 25, 2001	Group 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	DA	Afar et al., "Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia", Cancer Research 2001 61:1686-1692 XP-002229964	
	DB	Lin et al., "Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS2 ¹ ", Cancer Research 1999 59:4180-4184 XP-000929801	
	DC	Jacquinet et al., "Homo sapiens epitheliasin (TMPRSS2) mRNA, complete cds." 2001 Accession No. AF329454 XP-002229966	
	DE	Paoloni-Giacobino et al., "Homo serine protease mRNA, complete cds." 1997 Accession No. U75329 XP-002229965	
EXAMINER		DATE CONSIDERED	

Sheet 02 of 02

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. DEX-0196	Serial No. 09/807,201
	Applicant Salceda et al.	
	Filing Date April 25, 2001	Group 1642

U. S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation YES NO
EA	WO 99/67384	29-12-99	PCT	x

EXAMINER

DATE CONSIDERED